GALA-RIF, an 18-month, randomised, double-blind, placebo-controlled trial, showed that rifaximin-α did not lead to regression of liver fibrosis in patients with biopsy-confirmed alcohol-related liver disease. This evidence concerns the gene GLA and Hepatic fibrosis.